Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7530)	12/17/2002 8:49:49 PM
From: tom pope	Read Replies (1) \| Respond to of 52153

The whole sector may get a lift from the Flumist and Bexxar recommendations. Wonder if any particular stock will get more than others? IMCL, even tho the AH quotes don't any favorable reaction?

To: Vector1 who wrote (7530)	12/17/2002 9:20:42 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

V1, Congratulations to you as well - vindication at long last for your views on Bexxar. Do you have any sense from the briefing materials or from the AC meeting today of what lay behind the overall Bexxar debacle all these years? Was it the original CLTR decision not to do comparative trials but instead to compare the length of remission to the prior remission length? How much was it the FDA just being difficult and how much was it badly designed/conducted trials? Peter